ArticleFrontiers in medicine2025
The diagnostic value of serum inflammation, coagulation and tumor indexes in differentiating stage III and IV ovarian endometriotic cysts.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian endometriotic cysts (OEC) are classified into early (I-II) and advanced (III-IV) stages. Stage IV OEC is characterized by severe adhesions and anatomical distortion that complicate surgical management. Accurate preoperative differentiation between stage III and IV OEC is crucial for optimizing surgical planning and patient outcomes. Objective: This study aimed to investigate the diagnostic value of serum inflammatory, coagulation, and tumor markers in differentiating stage III from stage IV OEC. Methods: This retrospective study analyzed 205 patients with histopathologically confirmed stage III ( Results: Stage IV patients demonstrated significantly elevated platelet-to-lymphocyte ratio (PLR), thrombin time, fibrinogen (FIB) levels, and carbohydrate antigen 125 (CA125) concentrations compared to stage III patients. Multivariate analysis identified PLR, FIB, and CA125 as independent predictors of stage IV OEC. The combined nomogram (PLR, FIB, and CA125) achieved superior diagnostic performance with an AUC of 0.81 (95% CI: 0.75-0.88) in the training cohort and 0.78 (95% CI: 0.65-0.91) in the test cohort, outperforming individual biomarkers. Conclusion: The integration of PLR, FIB, and CA125 provides a practical, non-invasive, and cost-effective approach for preoperative differentiation of stage III and IV OEC, which potentially facilitates improved surgical planning and personalized patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.